Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | CDC25A | P30304 | 6/20 | 0.36 |
| ▸ | CDC25B | P30305 | 6/20 | 0.36 |
| ▸ | CDC25C | P30307 | 5/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5734668 | 0.81 | PPARA (0.33) | PPARA | |
| SCHEMBL4564307 | 0.74 | GAA (0.41) | ALDH1A1PPARAHCAR3HCAR2 | |
| SCHEMBL9273861 | 0.73 | KDM4E (0.36) | ALDH1A1HPGDMAPT | |
| SCHEMBL8995000 | 0.72 | TLR8 (0.38) | PPARASMN1; SMN2 | |
| SCHEMBL8995096 | 0.71 | ALOX5 (0.36) | ALDH1A1PPARAPTGS2 | |
| SCHEMBL285375 | 0.70 | GCGR (0.40) | — | |
| SCHEMBL11418567 | 0.70 | NPC1 (0.40) | PPARAHCAR3HCAR2 | |
| SCHEMBL9536320 | 0.70 | PPARA (0.38) | PPARAHPGDHSD17B10MAPTHCAR3 | |
| SCHEMBL17514350 | 0.69 | MLYCD (0.40) | ALDH1A1PPARAHPGD | |
| SCHEMBL28212760 | 0.66 | TYR (0.36) | ALDH1A1PPARAPTGS2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3220180-A | — | — | None | — | — | JP | disclosed |
| JP-3161464-A | — | — | None | — | — | JP | disclosed |
| US-20100069443-A1 | COMPOUND WITH BENZAMIDE SKELETON HAVING CYCLOOXYGENASE-1 (COX-1)-SELECTIVE INHIBITORY ACTIVITY | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2070908-A1 | COMPOUND HAVING BENZAMIDE SKELETON AND CYCLOOXYGENASE (COX-1)-SELECTIVE INHIBITORY ACTIVITY | National University Corporation Okayama University (JP) | 2009-06-17 | — | — | EP | disclosed |
| CN-1214790-C | Medicinal composition for treating inflammation | SEARLE & CO (US) | 2005-08-17 | — | — | CN | disclosed |
| EP-1528059-A2 | Substituted isoxazoles for the treatment of inflammation | G.D. Searle LLC (US) | 2005-05-04 | — | — | EP | disclosed |
| CN-1442139-A | Medicinal composition for treating inflammation | SEARLE & CO (US) | 2003-09-17 | — | — | CN | disclosed |
| CN-1107058-C | Substituted isoxazoles for the treatment of disorders | SEARLE & CO (US) | 2003-04-30 | — | — | CN | disclosed |
| EP-0809636-B1 | SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-09-04 | — | — | EP | disclosed |
| US-5985902-A | TREATING INFLAMMATION AND INFLAMMATION-ASSOCIATED DISORDERS, SUCH AS ARTHRITIS | G.D. SEARLE & CO. (US) | 1999-11-16 | — | — | US | disclosed |
| US-5142091-A | α, β-unsaturated ketones and ketoxime derivatives | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1992-08-25 | — | — | US | disclosed |
| US-5142091-A | α, β-unsaturated ketones and ketoxime derivatives | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1992-08-25 | — | — | US | disclosed |
| EP-0464218-A1 | PROCESS FOR PRODUCING ISOXAZOLE DERIVATIVE | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1992-01-08 | — | — | EP | disclosed |
| EP-0464218-A1 | PROCESS FOR PRODUCING ISOXAZOLE DERIVATIVE | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1992-01-08 | — | — | EP | disclosed |
| EP-0454871-A1 | ALPHA, BETA-UNSATURATED KETONE AND KETOXIME DERIVATIVE | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1991-11-06 | — | — | EP | disclosed |
| EP-0454871-A1 | ALPHA, BETA-UNSATURATED KETONE AND KETOXIME DERIVATIVE | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1991-11-06 | — | — | EP | disclosed |
| JP-H03220180-A | ISOXAZOLINE DERIVATIVE | TAIHO YAKUHIN KOGYO KK | 1991-09-27 | — | — | JP | disclosed |
| WO-1991011443-A1 | PROCESS FOR PRODUCING ISOXAZOLE DERIVATIVE | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1991-08-08 | — | — | WO | disclosed |
| JP-H03161464-A | ALPHA,BETA-UNSATURATED KETONE AND KETOXIME DERIVATIVE | TAIHO YAKUHIN KOGYO KK | 1991-07-11 | — | — | JP | disclosed |
| WO-1991007374-A1 | α,β-UNSATURATED KETONE AND KETOXIME DERIVATIVE | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1991-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069443-A1 | COMPOUND WITH BENZAMIDE SKELETON HAVING CYCLOOXYGENASE-1 (COX-1)-SELECTIVE INHIBITORY ACTIVITY | PTGS1, PTGS2, PTGIS | ALDH1A1 56/4885PPARA 1339/4885PTGS2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.